Pacira | PCRX - Operating Expenses


Pacira reported $166.36M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Assertio Holdings USD 105.8M 12.5M Sep/2025
Astellas Pharma JPY 436.66B 16.75B Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Cara Therapeutics USD 4.96M 2.38M Mar/2025
Coherus Biosciences USD 53.03M 43.41M Mar/2025
Heron Therapeutics USD 38.47M 4M Sep/2024
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 18.97B 2.38B Dec/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Novo Nordisk DKK 46.76B 3.99B Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 166.36M 4.5M Sep/2025
Perrigo USD 949.9M 50.8M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Supernus Pharmaceuticals USD 252.29M 98.98M Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Xeris Pharmaceuticals USD 67.65M 590K Sep/2025
Xoma USD 22.84M 1.67M Sep/2024
Zoetis USD 1.55B 3.85B Dec/2025